http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2009127795-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0215 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-107 |
| filingDate | 2007-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2011-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2009127795-A |
| titleOfInvention | PHARMACEUTALLY ACCEPTABLE THIMODEPRESSIN SALTS AND METHOD FOR PRODUCING THEM |
| abstract | 1. A pharmaceutically acceptable salt of D-isoglutamyl-D-tryptophan of formula I! ! where M is selected from the group consisting of potassium and lithium. ! 2. The pharmaceutically acceptable salt of claim 1, wherein M is potassium and the salt is in amorphous form. ! 3. The pharmaceutically acceptable salt of claim 1, wherein M is potassium and the salt is in crystalline form. ! 4. The pharmaceutically acceptable salt according to claim 3, which is a potassium salt of D-isoglutamyl-D-tryptophan, which is characterized by peaks in a powder x-ray in the range of the following 2-θ values: 9.91, 14.84, 15.81, 18, 97, 19.76, 24.04, 24.36, 24.82, 25.48, 27.49, 27.94, 28.42, 30.82, 31.28, 31.69, 32.17, 34.35, 35.81 and 36.96 °. ! 5. The pharmaceutically acceptable salt according to claim 3, which is a potassium salt of D-isoglutamyl-D-tryptophan, which is characterized by a powder x-ray shown in figa. ! 6. The pharmaceutically acceptable salt according to claim 1, characterized in that M is lithium and the salt is in amorphous form. ! 7. The pharmaceutically acceptable salt according to claim 1, characterized in that M is lithium, and the salt is in crystalline form. ! 8. The pharmaceutically acceptable salt according to claim 7, which is a lithium salt of D-isoglutamyl-D-tryptophan, which is characterized by peaks in a powder x-ray in the range of the following 2-θ values: 13.57, 15.53, 18.71, 20, 11, 23.34, 24.1, 25.09, 27.31, 27.72, 28.39, 29.31, 30.19, 31.21, 32.06, 33.05, 33.62 and 37.41 °. ! 9. The pharmaceutically acceptable salt according to claim 7, which is a lithium salt of D-isoglutamyl-D-tryptophan, which is characterized by a powder x-ray shown in figa. ! 10. A pharmaceutically acceptable salt of D-isoglutamyl-D-tryptophan of formula II! ! Where |
| priorityDate | 2006-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 60.